PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
PVCT$0.04-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
FOR THE THREE MONTHS ENDED MARCH 31, 2025
| Preferred Stock · Preferred Stock · Additional · Accumulated Other | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated · Noncontrolling | |||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Interest | Total | |
| Balance at January 1, 2025 | 956,985 | $957 | 13,106,223 | $13,106 | 420,279,879 | $420,280 | $251,090,027 | $(60,741) | $(257,422,961) | $(9,893) | $(5,969,225) |
| Issuance of common stock of majority owned subsidiary | - | - | - | - | - | - | 634,782 | - | - | 65,218 | 700,000 |
| Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock | - | - | 365,400 | 365 | - | - | 1,046,329 | - | - | - | 1,046,694 |
| Stock-based compensation | |||||||||||
| Stock Options | - | - | - | - | - | - | 315,100 | - | - | - | 315,100 |
| Comprehensive loss: | |||||||||||
| Net loss | - | - | - | - | - | - | - | - | (1,140,108) | (21,494) | (1,161,602) |
| Other comprehensive income | - | - | - | - | - | - | - | 52 | - | - | 52 |
| Balance at March 31, 2025 | 956,985 | $957 | 13,471,623 | $13,471 | 420,279,879 | $420,280 | $253,086,238 | $(60,689) | $(258,563,069) | $33,831 | $(5,068,981) |
FOR THE THREE MONTHS ENDED MARCH 31, 2024
| Preferred Stock · Preferred Stock · Additional · Accumulated Other | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated | ||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Total | |
| Balance at January 1, 2024 | 12,373,247 | $12,373 | 10,361,097 | $10,361 | 419,522,119 | $419,522 | $244,714,967 | $(60,165) | $(252,690,409) | $(7,593,351) |
| Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock | - | - | 226,474 | 226 | - | - | 647,935 | - | - | 648,161 |
| Comprehensive loss: | ||||||||||
| Net loss | - | - | - | - | - | - | - | - | (504,042) | (504,042) |
| Other comprehensive loss | - | - | - | - | - | - | - | (415) | - | (415) |
| Balance at March 31, 2024 | 12,373,247 | $12,373 | 10,587,571 | $10,587 | 419,522,119 | $419,522 | $245,362,902 | $(60,580) | $(253,194,451) | $(7,449,647) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.